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The lack of a satisfactory animal model has greatly complicated the study of 
immunity to systemic meningococcal disease. Mucin-enhanced infection, albeit 
unsatisfactory, is the only model presently available (1). The studies of Scherp 
and Rake (2), Watson and Scherp (3), and Kabat et al. (4) with hyperimmune 
sera of several animal species and convalescent sera of man indicated that anti- 
bodies to the group-specific polysaccharides were able to passively protect mice 
against fatal meningococcal infection. Goldschneider et al.  (5)  have demon- 
strated that the presence in human serum of antibodies to meningococcal anti- 
gens, as measured by the bactericidal reaction, is strongly correlated with im- 
munity to meningococcal  disease. In many of the sera studied, it could be shown 
that a large part of the bactericidal antibody was directed against the group 
C-specific polysaccharide (6). These lines of evidence indicate that if antibodies 
to the group-specific polysaccharides  could be induced artificially, they probably 
would be protective. 
Kabat et al. (7) investigated the immunogenicity of the group A polysac. 
charide in human volunteers. They found it to be a poor antigen. Kabat also 
iniected several human volunteers with the group C polysaccharide prepared 
by Watson and Scherp (3). The results were equally disappointing (8).  These 
polysaccharides probably all had average molecular weights of less than 50,000 
(9).  1 
Work on partially degraded dextrans has indicated that only if the molecular 
weight of polysaccharides is above 100,000 are the preparations reliably anti- 
genic in human beings (10). Gotschlich et al. (11) have shown that the group- 
specific A and C meningococcal polysaccharides, when isolated by the method 
employing the  cationic  detergent  Cetavlon,  have  high  average  molecular 
weights in excess of 100,000. These considerations prompted a reinvestigation 
of the immunogenicity in human beings of the meningococcal group A and C 
antigens. 
l IAu, T. Y., J. K. J6nsen, and E. C. Gotschlich. Manuscript in preparation. 
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Materials and Methods 
Antigens.--The  group-specific  meningococcal  polysaccharides  used  in  this  study  have 
been described in the preceding report  (11). Meningocoecal endotoxins were prepared by the 
hot phenol-water method of Westphal et al.  (12) from group A and group C mertingoeocci. 
The organisms were grown on the defined agar medium described by Catlin and Schloer (13), 
harvested  in  distilled water,  centtifllged,  and  washed  with  distilled water.  They were ex- 
tracted  twice with  hot  phenol-water  mixture.  The  aqueous  layers  were  pooled;  dialyzed 
extensively against  distilled water,  and  centrifuged at  100,000 g for 3 hr.  The pellets were 
suspended smoothly i  n 30 ml of water and ultracentrifuged for 3 hr at  100,000 g. This step 
was repeated once. The pellet was suspended in a minimal volume of water and lyophilyzed. 
Mudn-Enhanced  Infection in Mice.--Hog gastric  mucin  (granular mucin type  1701-W) 
was purchased from Wilson Laboratories, Chicago, Ill., and prepared as a  5% suspension in 
water, sterilized by autoclaving, and  neutralized with  1 ~  NaOH before use.  Meningococci 
were grown for 6 hr on Mueller-Hinton agar (14), and a suspension  containing approximately 
1 X  109 organisms/ml in phosphate-buffered saline was prepared as described by Goldsehnei- 
der et al.  (5).  The bacterial suspension was further diluted in mucin and an aliquot was re- 
moved and plated to assay the number of viable organisms. Inbred male and female mice of 
strain  C57BL/6  (Microbiological Associates,  Walkersville,  Md.),  weighing  20-25  g  were 
injected intraperitoneally with I  mi of mucin containing  the meningoeocei and observed for 
4 days. Most deaths occurred within 48 hr. 
Immuni~agion of Primates.--The immunogeulcity of group A polysaccharide lot A-1  and 
of C polysaceharide lot C-2 was tested in 12 rhesus monkeys weighing about 4 kg each. Three 
animals were injected with 25 #g of A polysaccharide intradermally, and were reinjected 25 
days  later with 20 #g of A  polysaccharide.  At the  time of the second injection, they also 
received 2 #g of C polysaccharide intradermally. Three other monkeys had the same immuni- 
zation schedule but  the  order of administration  of the antigens was  reversed.  All animals 
were bled immediately prior to the first injection and on days 14, 25, and 40 thereafter. Six 
other monkeys were injected intradermally with 2 #g of the same lots of polysaceharide used 
above, three with the A polysaccharide and three with the C polysaecharide antigen. These 
animals were bled 15 and 20 days after immunization. One rhesus monkey weighing about 10 
kg was injected intramuscularly with 50 #g of A polysaccharide lot A-1 absorbed onto alumi- 
num hydroxide gel, and was bled 14 and 40 days after injection. 
Eight chimpanzees were injected intradermally with 50 #g of polysaceharide, four of them 
with the A polysaceharide antigen, lot A-5, and the other four with C polysaceharide antigen, 
lot C-5. Two of the chimpanzees which were injected with A polysaccharide and two injected 
with C  polysaccharide had  undergone splenectomy prior to the present  study as part  of a 
study of experimental infection with malaria. The other four animals were normal. Bleedings 
were obtained at the time of injection, and on days  7 and 21 after immunization. 
Five gibbons at the SEATO Laboratories in Bangkok, Thailand, were injected  intrader- 
really with 25/~g of C polysaccharide, lot C-3, and were bled at weekly intervals for 4 wk. 
Toxicity Studies.--The general safety test employing guinea pigs as described in the Public 
Health Service Regulations (15), Section 73.72, was performed with 500/~g doses of meningo- 
coccal polysaccharide, lots C-4, C-5, and A-5. The pyrogenicity of lots C-4, C-5, and A-5 was 
tested in albino rabbits  (about 2.2 kg) as outlined in the Public Health Service Regulations 
(15),  Section 73.74. Interference with the growth rate of weanling mice was assayed by the 
method of Pittman and Cox (16). The method of Dubos and Schaedler (17) was used to assay 
for the presence of contaminating endotoxin. 
Sterility.--Sterility  of  the  meningococcai polysaccharide  prepared  for  human  use  (lots 
C-4, C-5, and A-5) was tested in bulk before final packaging and on 10% of the final packaged 
material, in accordance with the regulations of the Public Health Service (15), Section 73.73. GOTSCHLICH~  GOLDSCHNEIDER~  AND  ARTENSTEIN  1369 
Serological Metkods.--Passive hemagglutination was performed as described by Gotschlich 
et al. (11). Polysaccharides  from lot A-2 or C-2 were used to sensitize the red cells. The assay 
for bactericidal antibody and the hnmunofluorescent assay for antibody were performed as 
described by Goldschneider et al. (5). Fluorescein-conjugated rabbit sera against the heavy 
chains of human immunoglobulin A, G, and M were prepared by Behringwerke, Marburg- 
Lahn, Germany, and purchased from Hoechst Pharmaceutical Co., Kansas City, Mo. These 
companies also supplied the plates (Partigen) and method used for quantitative  radial im- 
munodiffnsion for the determination of the amount of the various immunoglobulins  in chroma- 
tographically separated serum. 
Gel Filtration of Human Serum.--I ml of serum was fractionated by gel filtration on Sepha- 
dex G-200  in a column designated K 15/90 (Pharma~a, Inc., Piscataway, N. J.). The protein 
concentrations in the eluates was determined by the absorbaney at 280 m/J. The buffer used 
was tris(hydroxymethyl) amlnomethane (Tris)-HCi, 0.1 M, pH 8.0. 
Human Sera.--Blood obtained from volunteers was allowed to clot at 37°C for 1 hr, cen- 
trifuged, and the major part of the serum stored frozen at --73°C. Small aliquots of serum 
were stored at 4°C. The latter samples were used for passive hemaggintination and for ring 
tests, whereas the frozen samples were used for all other studies. 
Cultures.--Nasopharyngeal cultures to determine the presence of meningococci were per- 
formed as described by Artenstein et al. (18). The serological  grouping was done by the method 
of Evans et al. (19). 
RESULTS 
The Immunogenicity of Higk Molecular Weigkt A  and C Meningococcal Poly- 
saccharides in Laboratory Animals.-- 
1.  Mice:  The  antigenicity  of the  meningococcal  polysaccharides  was  first 
tested in mice. This species was chosen because there is extensive experience on 
its  response  to  other  polysaccharides,  particularly  the  pneumococcal  type- 
specific antigens  (20).  The latter  work has delineated  the  optimum dose  of 
polysaccharide to be used for immunization  (0.1-1.0 gg) and the moment of 
maximum immunity (1  wk after immunization)  against a  challenge infection 
with living pneumococci (20). 
It has been shown that the majority of strain C57BL/6 mice succumb when 
injected with 10 or more meningococci suspended in 5 % hog gastric nlucin, and 
that these mice can be passively protected against fatal meningococcal infection 
by prior injection of antiserum. Several experiments were performed using this 
model. The results of one of these studies are shown in Table I. 
Mice  were injected  intraperitoneally with  the  appropriate polysaccharide. 
Doses of 0.05,  0.10, and 0.50 #g were employed. 1 wk later, the animals were 
challenged by intraperitoneal injection with approximately 100 meningococci 
suspended in mucin. This unusually  small dose was chosen to maximize the 
opportunity of observing active immunity. No protective effect was observed. 
In another experiment, mice immunized 1 wk before with 0.5 and 1.5/~g of A 
polysaccharide, lot A-l, were challenged with  1000  group A  meningococci of 
strain A1. All the animals died. The same result occurred when mice injected 
with 0.1  and  1.0 #g of C  polysaccharide, lot C-1, were challenged with  1000 
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2.  Primates: 13 rhesus monkeys were injected with various doses of the A and 
the C polysaccharide as described under Materials and Methods. Sera from the 
animals were tested for the presence of antibodies with the passive hemag- 
glutination test. No increases in taters were observed. 
Four chimpanzees were immunized with 50/,g of A polysaccharide, lot A-5, 
and four with an equal amount of C polysaccharide, lot C-5. None of the sera 
obtained  from  the  chimpanzees  showed  any increases  in  hemagglutAnation 
titers. 
Five gibbons were injected intradermally with 25/~g of C polysaccharide, lot 
C-3. No change in hemagglutination titers were observed in four of these ani- 
mals. However, one gibbon had a definite immune reaction; its hemagglutina- 
TABLE I 
Survivors among Mice Injected wilh Meningococcal  A or C Polysacd~aride and Challenged I Wk 
Later u~ith Meningococd S~pended in Mucin 
Immunization  Chafienge  No. of mice  Survivors 
Lot A-5, 0.05 #g 
LOt A-S, 0.10/~g 
LOt A-S, 0.50 #g 
Controls 
Lot C-5, 0.05/zg 
Lot C-5, 0.10 #g 
Lot C-5, 0.50/~g 
Controls 
100 A1 meningocoeci 
100 Cll meningococci 
~f  ~  Lc 
20 
20 
20 
20 
20 
20 
20 
20 
tion fiter rose from 1/8 to 1/128 within 1 wk of immunization and declined to 
1/64 over the next 2 wk. 
Toxicity of t~ Group-Specific Meningococcal  Antigens in Laboralory Animals. 
--Four tests to assay the toxicity of meningococcal polysaccharides were car- 
ded out in laboratory animals; two were designed to detect contamination with 
biologically active endotoxin, and the other two were general toxicity tests. 
Toxicity controls of polysaccharides, lots C-4, C-5, and A-S, prepared expressly 
for human use, were performed on final packaged material, which had passed 
the sterility tests. 
1.  Pyrogenicity in rabbits: A dose of 2.5 ~ag of Cat, C-S, or A-$ was injected 
intravenously into each of three albino rabbits. As a  positive control, other 
rabbits were injected with 0.010/zg of endotoxin isolated from the same menin- 
gococcal strains (/tl  and Cll)  used for the preparation of the group-specific 
polysaccharides. Rectal  temperatures  were  obtained  on  these  animals.  The 
results are set forth in Table II. 
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exhibit any perceptible  pyrogenic responses. However, the six animals injected 
with 0.010 pg of endotoxin from strain A1 or Cll had definite febrile resPonses. 
This experiment indicates that the Polysaccharides contained less than 1% by 
weight of biologically active endotoxin. 
2.  Inh~ion  of drinking by mlc~: The  absence  of  significant  amounts  of 
endotoxin was also demonstrated by the test described by Dubos and Schaedler 
(17). Normal mice gain weight overnight primarily because  of water intake. 
However,  animals injected with endotoxin do not drink normally and show a 
TABLE H 
Temperature Response of Rabbits to the In2ravcnous Injection of Meningococcal 
Polysaccharides or Endotoxins 
Rabbit 
10 
11 
12 
13 
14 
15 
Inoculation  Initial  ~ hr  1  hr  136 hr  2  hr  3 hr 
Polysaccharide, lot C4,  39.5  39.4  39.3  39.4  39.4  39.3 
2.5/~g  39.0  39.0  39.0  39.0  39.0  38.8 
39.0  38.8  38.7  38.6  38.7  38.7 
Polysaccharide, lot C-5,  39.0  38.7  38.9  38.8  38.7  38.6 
2.5 ~g  39.9  39.8  39.8  39.8  39.6  39.5 
39.0  39.0  38.8  38.7  38.6  38.5 
Endotoxin, strain Cll,  39.8  40.0  40.3  40.4  40.3  40.1 
0.01 #g  39.6  39.9  40.7  40.8  40.5  40.3 
39.0  39.1  40.2  40.8  40.3  40.1 
Polysaccharide,  lot A-5,  39.1  39.0  39.1  39.1  39.4  39.3 
2.5/~g  39.2  39.2  39.3  39.3  39.3  39.2 
39.0  39.1  39.3  39.3  39.3  39.3 
Endotoxln, strain A1,  38.7  38.4  39.6  39.9  40.1  39.6 
0.01/zg  38.7  38.7  39.5  39.9  39.8  39.4 
38.1  38.0  39.9  39.9  39.7  39.4 
weight loss overnight. Mice were weighed mad injected at 4 p.m. with 100 ~g of 
polyssccharide or with either 1.0 or 0.5/~g of meningococcal endotoxin. Water 
and food were suppUed ad lib. The animals were weighed the next morning and 
the average weight change per mouse was calculated. The results of four experi- 
ments are shown in Table HI. 
The mice injected with polysaccharlde generally gained less weight than con- 
trol animals injected with saline. The injection of one preparation,  lot C-3, 
caused a loss of weight. However, in no experiment did the mice injected with 
polysaccharide lose as much weight as the animals injected with 0.S ~g or 1 ~ag 
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3.  Growth of weanling mice: One of the general toxicity tests employed deter- 
mined the effect upon the growth rate of weanling mice resulting from the injec- 
t-ion  with  meningococcal  polysaccharides  (16).  Male  or  female  albino  mice 
weighing 14-16 g were injected with 100 #g of the various lots of polysaccharide, 
and their weights were observed for 1 wk. Table IV indicates the average weight 
gain per mouse over the 7 day period. It should be noted that the female mice 
TABLE III 
Average Overnight Weight Change of Mice Inoculated with Meningococcal Polysaccharides or 
Endotoxins 
Exp.  Test substance  1~o. of mice  Weight gain  injected  per mouse 
Saline control 
Lot A-l, 100 #g 
Lot A-2, 100/~g 
Lot C-2, 100 #g 
A endotoxin, 1.0 #g 
C endotoxin, 1.0 #g 
Saline control 
Lot C-3, 100 #g 
Lot A-3, 100 #g 
C endotoxin, 0.5 #g 
Saline control 
Lot C-4, 100/zg 
Lot C-5, 100 #g 
C endotoxin, 0.5 #g 
Saline control 
Lot A-5, 100 #g 
A endotoxin, 0.5 #g 
15 
5 
5 
5 
5 
5 
15 
15 
15 
15 
20 
15 
15 
15 
20 
20 
20 
g 
+1.40 
+1.60: 
+1.00 
+0.30 
--0.52 
--1.20 
+0.93 
--0.87 
+0.87 
--2.24 
+I .20 
+0.92 
+0.88 
--1.98 
+0.42 
+0.31 
--0.58 
used in the third and fourth experiments gained weight more slowly than males. 
The experiment was done twice with lot A-5. The growth rate of the mice in- 
jected with polysaccharide was no different than that of animals injected with 
saline. 
4.  Toxicity for guinea pigs: The other general safety test is one  required  by 
federal  regulations  for  biological  products  (15).  Three  guinea  pigs  weighing 
about 350 g were injected with 500 #g of each lot of polysaccharide and their 
weights and temperatures were observed for 1 wk. The lots of polysaccharide 
C-4,  C-5,  and A-5  were tested  by this method.  The animals showed normal 
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The Immunogenicity of High Molecular Weight A  and C Meningococcal Poly- 
saccharides  in Human  Volunteers.--The  immunogenicity of the  group-specific 
polysaccharides was first tested in one volunteer and then in an additional five. 
All of the volunteers were males ranging in age from 24 to 38 yr, and were labo- 
ratory personnel. One of the subjects was a Negro, the others Caucasian. Throat 
cultures were obtained at the beginning of the study, at weekly intervals for 4 
wk  and occasionally thereafter, and were examined for the presence of meningo- 
cocci  (18,  19).  All  cultures were negative  except for subject  I.G.  who had 
TABLE IV 
The Effect of Meningococcal Polysaccharidea on the Growth Rate of Weanling Mice* 
Exp.  Test substance  No.  of mice  Weight gain  per mouse 
4 
Saline control 
Lot C-4, 100 #g 
Lot C-5, 100 .ug 
Saline control 
Lot A-5, 100 #g 
Saline control 
Lot A-5, 100 #g 
Saline control 
Lot A-2, 100/zg 
Lot A-3, 100 #g 
Lot C-2, 100/zg 
Lot C-3, 100 #g 
20 
20 
20 
25 
20 
40 
25 
10 
10 
10 
10 
10 
g 
+8.32 
+8.3O 
+8.12 
+9.00 
+7.60 
+4.52 
+5.07 
+6.10 
+6:00 
+6 .50 
+6.10 
+5.90 
* Experiments 1 and 2 were done with male mice; Experiments 3 and 4 with female mice. 
recently acquired a group B meningococcus. Subject J.W. was known to have 
carried group C meningococci until about 4 months prior to this study. 
The subjects were bled and then injected intradermally in the forearm with 
0.20 ml of isotonic saline containing 50 pg of polysaccharide. The dates and the 
sequence of immunizations are indicated in Table VII. The subjects were asked 
to report any signs or symptoms of toxicity and to measure their temperature 8 
hr after the injection. None of the volunteers had any signs of systemic toxicity 
and no febrile responses occurred. 
All subjects showed a skin reaction to the injections. There were no immediate 
wheal and erythema reactions. About 4  hr after the injection, a  pale orange 
discoloration occurred which was limited to the site of the bleb. One subject 
(E. C. G.  injected with A-2)  reported mild itching locally which disappeared 1374  rMMUNITY TO MENINGOCOCCUS. IV 
within 6hr. At about 8 hr, all subjects reported an area of erythema and some- 
times slight induration around the site of injection. The reactions ranged up to 
50 mm in diameter, were slightly tender, and reached maximum dimensions by 
20 hr. They then faded completely over the next 48 hr, leaving in most in- 
stances an area of pigmentation about 10 mm in diameter which disappeared in 
about 2 wk. 
Serum specimens were collected at weekly intervals for 4 wk and occasionally 
thereafter. Antibody responses were measured by several methods, 
1.  HemaggluZinaZing antibodies: Results in  Tables V  and  VI show that  all 
subjects responded with the production of hemagglutinating antibody within 
1 wk of injection of polysaccharide and reached peak titers within 2 wk. The 
TABLE V 
Reciprocal Hemagglulinalion Tieers of Six Subjects Irn~nunized with Meningococcal C 
Polysaccharide* 
Weeks following  immunization  with C  antigen 
Subjects 
0  1  2  3  4  20  35 
M. S. A. 
W. C. B. 
I.G. 
E, C. G. 
J.S. 
J.W. 
2 
2 
2 
2 
2 
32 
64 
32 
32 
128 
64 
64 
256 
256 
128 
256 
64 
128 
256 
256 
128 
128 
64 
128 
256 
256 
128 
64 
128 
6 
256 
128 
64 
128 
512 
256 
128 
128 
64 
128 
128 
* Cells sensitized  with C polysaccharide. 
geometric mean of the reciprocal titers was 161 for the response to the C poly- 
sacchaHde, and 446 for the response to the A  polysaccharide. The titers re- 
mained unchanged or dropped one 2-fold dilution during the remainder of the 
study.  Subject J.  W. was known to have been a  group C  carrier until a  few 
months before this Study, and this probably accounts for his initial titer of 1/32 
against red ceils sensitized with the C antigen. Due to the nature of the hemag- 
glutination system, the other initial titers should not be interpreted as indicat- 
ing either the presence or absence of antibodies. What is of interest are the pro- 
nounced increases in titer following the injection of the antigens. 
2.  Precipitaging  antibodies: The sera of these subjects were also tested quali- 
tatively for the presence of precipitating antibody employing the ring test. All 
subjects except J. S. had detectable precipitating antibodies to the A and the C 
polysaccharide within 2 wk after injection with the respective antigen. The sera 
of subject J.  S. did not at any time produce a  positive ring test with either 
antigen. 
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the ;mrnunizations was tested by measuring the bactericidal activity of the sera 
agdast four test strains of meningococci in the presence of an exogenous source 
of human complement. Two of the test organisms belonged to group A and the 
other 2 to group C. The results are set forth in Table VII. 
AU subjects,  except E. C. G., were injected first with the C polysaccharide. 
Their bactericidal activities to the group C test organisms  rose to full titer 
within a week or two. Subject J. W., who had been a group C carrier and had a 
very high initial bactericidal titer to the group C organisms, nevertheless  ex- 
perienced  a  considerable  rise in activity after the injection with C polysac- 
charide. None of the subjects had increases in bactericidal activity to the group 
A test organisms  as a  result of injection with the C polysaccharide,  but all 
volunteers did produce bactericidal antibody to the group A test organisms in 
TABLE  VI 
Reciprocal  He.~ggl~in~ion  Ti~s o/Pi~e Sub]~l.~  Immu.ised wilk  Meningococc~d  .4 
Polysaccharide* 
Weeks following  immunization  with A  ant.lge~  ,'" 
Subjects 
0  I  2  4  18  37 
M. S. A. 
I.G. 
E. C. G. 
J.S. 
J.W. 
8 
32 
8 
16 
16 
128 
128 
128 
64 
512 
1024 
512 
512 
128 
512 
1024 
512 
512 
128 
512 
512 
~256 
256 
64 
512 
256 
* Cells  sensitized  with A polysaccharide. 
response to injection with the A polysaccharide.  Subject W. C. B. was not in- 
jected with the A polysaccharide  and never developed  increased  bactericidal 
activity to the group A test organisms. Subject I. G. showed the same pattern 
of increases in bactericidal response even though he was a carrier of group B 
meningococci. 
The order of the immunizations was reversed  for subject E. C. G. and it 
should be noted that injection with the A polysaccharide  did not increase the 
bactericidal activity against the group C test organisms. The bactericidal ac- 
tivity d  the sera obtained from this subject was tested  against a  greater num- 
ber of meningococcal strains and the results are presented in Table VIII. 
After  immunization  with  the  polysaccharide  antigens,  there  were  demon- 
strable increases in bactericidal activity to all strains of meningococci belonging 
to group A or group C. However, no increases in bactericidal activity occurred 
to organisms belonging to group B  or to 135 (19). 
Nature of theAntibody Responseto MeningococcalGroup  Speclf~ Polysaccharides. 
--The classes of antibody produced in the blood of human volunteers after in- TABLE  VII 
Serum  Bac~3ricidd  Antibody in  Six  Subjexls after Immunization  wilh  Meningococcal  Group- 
Specific Polysaccharides 
Subject 
M,S.A. 
S April 
12  " 
19  " 
26  " 
3 May 
13 August 
W.C.B. 
1 April 
12  " 
18  " 
26  " 
3 May 
13 August 
/.G. 
2 April 
12  " 
19  " 
26  " 
3 May 
17 May 
13 August 
g. C. G. 
30 November 
7 December 
II  " 
14  " 
21  " 
28  " 
5 January 
13 August 
J.S. 
2 April 
12  " 
19  " 
26  " 
3 May 
17  " 
26 August 
Immunogen 
c-s,  5 April 
A-5, 19 April 
c-5, 5 Apr~ 
c-5, 5 Apra 
A-5, 19 April 
A-2, 30 November 
C-2,  14 December 
C-5, 5 April 
A-5, 19 April 
Reciprocal bactericidal titer against 
Group A strains  Group C strains 
AI  121 misc.  Cll  107 VI 
4  4  16  16 
4  4  128  512 
4  4  2048  1024 
32  32  2048  1024 
128  256  2048  1024 
256  256  2048  2048 
4  4  8  8 
4  4  16  64 
4  4  128  256 
4  4  128  256 
4  8  128  256 
4  4  128  256 
32  32  16  16 
32  16  32  64 
32  16  256  512 
32  128  256  256 
64  256  256  512 
64  256  256  512 
128  256  256  512 
4  8  8  4 
8  16  8 
64  128 
64  128  8  4 
64  128  256  256 
64  128  256  512 
64  256  256  512 
128  256  128  512 
8  8  4  4 
8  8  64  64 
8  16  256  256 
32  64  256  256 
32  128  256  256 
32  64  512  256 
32  32  256  256 
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Subject 
J.W. 
2 April 
12  " 
19  " 
26  " 
3 May 
17  " 
13 August 
Immunogen 
c-s, 5 AprU 
A-5, 19 April 
Reciprocal bactericidal tlter against 
Group A strains  Group C Strains 
A1  121 misc.  Cli 
8 
8 
8 
128 
256 
256 
256 
8 
8 
8 
128 
256 
256 
256 
107VI 
128  256 
256  1024 
1024  1024 
1024  1024 
1024  1024 
1024  1024 
512  512 
TABLE VIII 
Bactericidal  AaidSy  of Preimmune  and  Immune  Serum  of Subjea  E.C,G.  againa  Various 
Meningococcal Strains 
Meningococcal  strain 
A-1 
120-Misc 
121-Misc 
C-11 
182-I 
91-11 
176-III 
158-IV 
140-V 
107-VI 
85-III 
122-Misc 
166-IV 
169-III 
153-I 
Serogroup 
A 
A 
A 
C 
C 
C 
C 
C 
C 
C 
B 
135 
B 
B 
B 
Reciprocal becterlcldal tlter 
ECG, November 30  ECG, February 21 
64 
64 
128 
256 
256 
128 
256 
128 
128 
512 
8 
8 
8 
4 
8 
jection with the meningococcal group-specific polysaccharides were studied by 
indirect immunofluorescence. IgG, IgM,  and IgA antibodies were specifically 
identified using  fluorescein-conjugated  rabbit  antisera  prepared  against  the 
heavy chains of human immunoglobulins. Antibody titrations were done, using 
group A  or group C  meningococci, according to the method of Goldschneider 
et al. (5). 1378  IMMUNITY  TO  MENINGOCOCCUS.  IV 
TABLE IX 
Semiquantitati~e  Determination  of tl~ Amount  of An~imeningococcal Antibodies  in  Each 
Immunoglobulin  Class in the Se~a of Six  Volunteers Immunized with 
Meningococcal Group-specifw  Polysaccharides. 
Subject 
M.S.A. 
5 April 
12  " 
19  " 
26  " 
3 May 
13 August 
W,C.B. 
1 April 
12  " 
18  " 
26  " 
3 May 
13 August 
I.G. 
2 April 
12  " 
19  " 
26  " 
17 May 
13 August 
E.C.G. 
30 November 
11 December 
14 
21  " 
28  " 
18 January 
21 February 
13 August 
Immtmogen 
Reciprocal immunofluoreacence  titers 
with antibodies to human 
immunoglobulins 
Immuno-  Immuno-  Immuno- 
globulin G  globulin M  globulin A 
AI*  Cll*  A!  Cll  A1  C11 
LOt C-5,5April  <4  4  <4  <4  2  <4 
<4  64  <4  16  2  32 
Lot A-5, 19April  <4  256  <4  32  2  256 
32  256  16  64  32  256 
256  256  128  64  128  256 
128  256  64  64  64  128 
LOt C-5, 5 April 
Lot C-5, 5 April 
Lot A-5, 19 April 
Lot A-2, 30 November 
Lot C-2,  14 December 
4  4  8  4  8  8 
4  32  8  32  8  8 
4  128  8  128  8  128 
4  256  8  128  8  128 
4  128  8  128  8  128 
4  128  4  64  8  64 
16  16  8  8  16  8 
32  64  16  32  32  32 
32  128  16  64  32  128 
256  128  64  64  128  128 
256  128  64  64  128  128 
256  128  64  32  64  64 
4  4  ~2  2  <2  <2 
32  --  8  --  16 
64  4  16  2  32  <2 
64  --  32  --  32 
128  64  16  32  16  32 
128  64  32  32  32  16 
64  128  32  32  32  32 
128  64  32  32  32  32 
* A1  and  Cll  refer to a  group A  and group C  meningococcal strain respectively. These 
organisms were allowed to dryon microscope slides, exposed to 2-fold dilutions of the human 
sera, and stained with antisera to human immunoglobulin G, M, and A. GOTSCHLICH~ GOLDSCB~TEIDF--~,  AND ARTENSTEIN 
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Subject 
3. S. 
2 April 
12  " 
19  " 
26  " 
3 May 
17  " 
26 August 
J. W. 
2 April 
12  " 
19  " 
26  " 
3 May 
17  " 
13 August 
Innnunogen 
Lot C-5, 5 April 
Lot A-5, 19 April 
Lot C-5, 5 April 
Lot A-5, 19 April 
Immuno-  Immuno- 
globulin  G  globulin  M 
A1  Cll 
8  4 
8  64 
16  64 
32  128 
64  128 
64  128 
64  128 
A1  Cll 
<4  4 
<4  32 
<4  32 
32  128 
32  128 
32  128 
32  64 
16  32  8  16 
16  32  8  64 
16  128  8  64 
128  256  32  64 
256  256  256  64 
256  256  256  64 
256  256  128  32 
Immuno- 
globulin A 
AI  Cll 
<4  4 
<4  16 
<4  32 
64  128 
128  128 
64  128 
32  64 
8  4 
8  16 
8  128 
64  128 
256  128 
256  128 
128  64 
As a  result of the injection with the C  polysaccharide, the sera of subjects 
M. S. A., W. C. B., J. S., and J. W. contained significantly increased amounts of 
antibodies binding to group C meningococei, but not to group A organisms (see 
Table IX). Antibodies belonging to each of the three major classes of immuno- 
globulin  were  produced.  After  injection  with  the  A  polysaccharide,  similar 
antibodies capable of binding to group A meningococci appeared. The same was 
true for subject E. C. G., except that the order of the immunizations was re- 
versed. 
It should be remembered that this method, while specific in identifying what 
class of antibody is bound  to the meningococcal cells,  does not identify the 
antigen to which the antibody is bound. This may be pertinent in the interpreta- 
tion of the antibody response of subject I. G. who was a  carrier of group B 
meningococci during the study. His response does not appear to differ signifi- 
cantly from the responses of the  other subjects who were immunized by the 
same schedule. It is, however, possible that the slight rise in titer of antibody 
to group A  organisms which occurred prior to injection with A  polysaccharide 
was due to cross-rcactive antibodies resulting from his concurrent nasopharyn- 
geal infection. 
The Immunoglobulin Class of the Antibodies Responsible for tke Bactericidal 
Aaivity.mGoldschneider  et al.  (6) have shown that in serum from two normal 
adults the majority of the antibodies bactericidal to meningococci belonged to 1380  IMMUNITY TO MENINGOCOCCUS. IV 
the  immunoglobulin  G  class.  They also  demonstrated  that  the  bactericidal 
spectrum of maternal and cord serum was identical, further evidence that im- 
munoglobulin G  antibody is primarily responsible for the meningococcocidal 
activity, since cord serum contains essentially only this kind of antibody (5). 
In order to determine whether the artificially induced bactericidal activity 
mimicked the natural antibody response in this regard, an immune serum ob- 
tained from subject E. C. G. 37 wk after immunization with the A antigen was 
fractionated by gel filtration on Sephadex G-200. The elution profile is shown 
in Fig.  1. The contents of the odd tubes were sterilized by filtration through 
2.500 
2.000 
•  1.500 
o  ¢o 
"~  I.OOO 
0.500 
32 
16 
2.  30  3'5  4'o  K5  5'0  5'5  6'0  6'5  7'o  7~ 
Tube  No. 
Ihc.  1. The separation of human immune serum by Sephadex G-200 gel filtration. The 
elution profile represents the absorbance at 280 m#. The open bars indicate the hemagglu- 
tinating activity; the solid bars indicate the bactericidal activity in the presence  of exogenous 
complement. 
Millipore filters and assayed for their ability to kill group A meningococci in the 
presence of exogenous complement. The eluates in the even tubes were assayed 
for the presence of hemagglutinating antibody. The bactericidal and hemag- 
glutination titers are also entered in Fig. 1. 
The hemagglutinating  activity was separated into two peaks, whereas the 
bactericidal activity was found solely in the second peak. The eluates in tubes 
30, 48, and 60 were assayed for their content of immunoglobulin A, G, and M 
by  quantitative  radial  immunodiffusion  and  these  results  are  indicated  in 
Table X. 
It is clear from the elution profile and further confirmed by the results set 
forth in Table X  that the bactericidal activity of this serum could be recovered 
in the irnmunoglobulin G fraction. The first peak containing immunoglobulin A 
and M  had good hemagglutinating activity but no bactericidal power. GOTSCHLICH, GOLDSCHNEIDER, AND ARTENSTEIN  1381 
It should be mentioned that this serum also contained antibodies to the group 
C  polysaccharide, and that the duates were tested for bactericidal activity 
against a  group C  test organism, and for hemagglutinating activity with red 
cells coated with C polysaccharide. Surprisingly, both of these activities were 
completely absent. It was then realized that the fractionating coblmn had been 
used previously to assay the gel filtration behavior of a preparation of group C 
polysaccharide, and evidently enough antigen had remained adsorbed to the 
column to completely remove all antibodies directed to this polysaccharide. 
TABLE X 
The  Concentration of IgA,  IgG, and IgM  in  the Eluate  of Chromatographically Separated 
Human Immune Serum* 
Tube No. 
30 
48 
60 
IgG 
ms/t00 ~ 
<5 
85 
<5 
IgM 
mg/  lO0 ml 
21 
<3 
<3 
IgA 
mt/  lO0 n~ 
9 
<3 
<3 
* See Fig. 1. 
The concentrations  of immunoglobulins  were measured by radial immunodiffusion. 
DISCUSSION 
More than a score of large scale attempts have been made to develop a vac- 
cine to combat meningococcal meningitis (21).  Several of the vaccines were 
clearly ineffective, while others yielded inconclusive results. A vaccine prepared 
at the Pasteur Institute in Brazzaville from 1936 to 1939 was apparently suc- 
cessful. Unfortunately, the material produced by the same institute after World 
War II was no longer effective (21). More recently, Greenberg and Cooper (22) 
produced a soluble vaccine which has protective power for mice. 
The present study, which tests the antigenicity of high molecular weight 
group-specific meningococcal polysaccharides in man, represents a first step in 
the development of these polysaccharides as possible prophylactic immunizing 
agents. In the course of this study, the immunogenicity of four preparations of 
meningococcal polysaccharide were tested. None of these materials possessed 
significant toxicity for laboratory animals and no untoward reactions occurred 
among the six human volunteers. Subject J. W. had been a carrier of group C 
meningococci until 4 months preceding the study and had circulating antibodies 
to group C polysaccharide. His reaction to injection with  group  C  polysac- 
charide did not differ from the other volunteers. Both the A and the C polysac- 
charides proved to be good immunogens in man. This result is at variance with 
previous experiments (7, 8), but the polysaccharides tested prior to the present 
study were probably less than 50,000  average molecular weight (9).  1 It is our 1382  IMMUNITy  TO  MENINGOCOCCUS.  IV 
belief that the high molecular weight of the polysaccharides used in this study 
accounts for their immunogenicity, a hypothesis, which, however, has not been 
tested directly. 
Antibodies belonging to each of the three major classes of immunoglobulins 
were produced in response to a single intradermal injection with 50 ~g of A or C 
polysaccharides.  The sera of the six human volunteers became highly bacteri- 
cidal after immunization, killing all strains of group A or group C organisms 
tested. Peak titers were reached within 2 wk and the levels of bactericidal ac- 
tivity remained essentially unchanged for 5 months. This finding is in agreement 
with the experience that the human precipitating antibody response elicited by 
purified polysaccharides  is long lasting. Heidelberger  (23) reports that detect- 
able  antibody to type-specific pneumococcal  polysaccharide  was usually still 
present 3 yr after immunization and frequently as late as 8 yr. 
It was not possible to induce active immunity in mice with meningococcal 
polysaccharides, whereas this is readily accomplished with pneumococcal type- 
specific polysaccharides  (20, 24). It is not known whether this finding indicates 
that the meningococcal polysaccharides are not antigenic in the mouse, or that 
the deficiencies of the mucln-enhanced infection as an assay system negate the 
opportunity to observe an immune response. More sensitive methods for the 
detection of antibodies will have to be employed to settle this issue. An interest- 
ing development in this area is the recent study of Siskind et al. (25) employing 
isotopically labeled pneumococcal polysaccharide to measure quantitatively the 
immune response of the mouse. They found the greatest concentration of anti- 
body about 1 wk after immunization and a slow decline thereafter. Their data 
indicate that the average immune response of the mouse is about 10 times less 
than the average human response to this antigen (26). 
The present study has also tested the immunogenicity of the meningococcal 
polysaccharides in several primate species. There was no evidence for antibody 
production in rhesus monkeys or in chimpanzees. One out of five gibbons re- 
sponded, but the interpretation of such an isolated response is difficult. Study of 
the immunogenicity of meningococcal polysaccharides in this spedes should be 
pursued further. 
A new immunizing agent which is to be considered seriously for field trials 
should have certain attributes, among which are immunogenicity and lack of 
significant toxicity. Furthermore, there need be indications that the antibodies 
elicited are likely to be protective. It is felt that the present report shows that 
the high molecular weight group-specific meningococcal polysaccharides  fulfill 
these criteria and hence merit further attention to assess their value as prophy- 
lactic vaccines. 
SUMMARY 
High molecular weight group A and group C meningococcal polysaccharides 
had no significant toxicity for mice or guinea pigs. Furthermore, these polysac- GOTSCHLICH~ GOLDSCHNEIDER~ AND ARTENSTEIN  1383 
charide preparations contained negligible amounts of biologically active endo- 
toxin. 
The high  molecular weight group A  and  group  C  meningococcal polysac- 
charides were excellent immunogens in six human volunteers. Antibodies be- 
longing to the immunoglobulin classes IgG, IgM, and IgA were produced. 
These antibodies were highly meningococcocidal in the presence of comple- 
ment. 
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